Loading...

Gritstone bio, Inc.

GRTS•NASDAQ
Healthcare
Biotechnology
$0.03
$-0.01(-31.78%)

Gritstone bio, Inc. (GRTS) Stock Overview

Explore Gritstone bio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 59.7/100

Key Financials

Market Cap3.8M
P/E Ratio-0.05
EPS (TTM)$-1.09
ROE-3.22%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.33

GRTS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Gritstone bio, Inc. (GRTS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.33.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.05 and a market capitalization of 3.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for GRTSStats details for GRTS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$3.00
Average$4.00
High$5.00

Company Profile

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

CEO

Andrew R. Allen BCh, BM, MA, MRCP,

Employees

231

Headquarters

5959 Horton Street, EmeryVille, CA

Founded

2018

Frequently Asked Questions

;